Medpace Holdings, Inc. Announces Resignation of Thomas C. King to Board
January 04, 2023 at 02:58 am IST
Share
On December 31, 2022, Thomas C. King, a member of the Board of Directors of Medpace Holdings, Inc. notified the Company of his resignation from the Board, effective as of December 31, 2022. Mr. King's resignation did not result from any disagreement with the Company on any matter relating to its operations, policies or practices.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
MEDPACE HOLDINGS, INC. 
